Scholz, S. L.
Cosgarea, I.
Süßkind, D.
Murali, R.
Möller, I.
Reis, H.
Leonardelli, S.
Schilling, B.
Schimming, T.
Hadaschik, E.
Franklin, C.
Paschen, A.
Sucker, A.
Steuhl, K. P.
Schadendorf, D.
Westekemper, H.
Griewank, K. G.
Article History
Received: 3 December 2017
Revised: 27 January 2018
Accepted: 5 February 2018
First Online: 21 March 2018
Competing interests
: Dirk Schadendorf is on the advisory board or has received honararia from Roche, Genetech, Novartis, Amgen, GSK, Boehringer Ingelheim and Merck. The other authors declare no competing interests.